Multiple motor proteins regulate TDP-43 anterograde axonal transport - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Several motor proteins control anterograde axonal transport of TDP-43

  • By

  • Monica Feole

  • Victorio M. Pozo Devoto

  • Neda Dragišić

  • Maria Čarna

  • Katja Klosterman

  • Clara Limbaek-Stokin

  • Giancarlo Forte

  • Kenneth L. Moya

  • Richard A. Smith

  • Clive N. Svendsen

  • Gorazd B. Stokin

  • October 9, 2026

Share

Clinical Report: Several motor proteins control anterograde axonal transport of TDP-43

Overview

In H9-derived neurons, fluorescent TDP-43 showed processive anterograde axonal movement with kinetics comparable to vesicular cargoes. Biochemical and proximity-ligation analyses found associations with transport machinery, including KIF5A, KIF5B, and KIF5C through KLC1, as well as KIF1A. The findings support a multi-motor transport model for TDP-43-containing ribonucleoprotein complexes, while the contribution of transport disruption to ALS pathology remains unresolved.

Background

TDP-43 is an RNA-binding protein involved in RNA metabolism, with nuclear roles in transcription and splicing and cytoplasmic roles in mRNA trafficking and local translation. Its pathology is associated with ALS, FTLD-TDP-43, and LATE, among other neurodegenerative disorders. In approximately 97% of sporadic ALS cases, the source describes nuclear depletion alongside aberrant cytoplasmic accumulation and aggregation. These changes can affect both nuclear RNA processing and cytoplasmic mRNA transport, processes relevant to axonal and synaptic function.

Data Highlights

Measure or observationFinding reported in source
Sporadic ALS with nuclear TDP-43 depletion and aberrant cytoplasmic accumulationApproximately 97%
Neuronal modelH9 embryonic stem-cell-derived neurons
Axonal movementProcessive anterograde TDP-43 movement; kinetics comparable to vesicular cargoes
Kinesin associationsKIF5A, KIF5B, and KIF5C via KLC1; also KIF1A

Key Findings

  • Live-cell imaging and segmental trajectory analysis showed processive anterograde movement of TDP-43 in H9-derived neuronal axons.
  • TDP-43 movement kinetics were reported as comparable to those of vesicular cargoes, including Rab5, synaptophysin, and APP used as reference cargoes.
  • Biochemical assays and proximity-ligation analyses demonstrated interactions between TDP-43 and anterograde and retrograde transport machinery, consistent with a bidirectional transport profile.
  • TDP-43 interacted with all three kinesin-1 isoforms—KIF5A, KIF5B, and KIF5C—via kinesin light chain 1 (KLC1).
  • The study also found an interaction with KIF1A, a kinesin-3 family member.
  • The source proposes that TDP-43-containing membraneless organelles may use a flexible multi-motor transport arrangement; whether transport disruption contributes to ALS pathology remains uncertain.

Clinical Implications

The findings characterize candidate motor-protein associations and axonal transport behavior in a neuronal cell model; the source does not establish a clinical diagnostic or treatment application. The relationship between altered TDP-43 transport and ALS disease mechanisms remains an open question in the material provided.

Conclusion

TDP-43 undergoes anterograde axonal transport and associates with multiple kinesin motors, alongside evidence of interaction with retrograde machinery. The results support a multi-motor model but do not resolve how transport changes relate to neurodegeneration.

Related Resources & Content

  1. Article source, Several motor proteins control anterograde axonal transport of TDP-43, year not provided
  2. Acta Neuropathologica, Protein Misfolding in Amyotrophic Lateral Sclerosis, 2013
  3. Acta Neuropathologica, Altered TDP-43 in Motor Neurons Initiates but Does Not Advance Disease in Amyotrophic Lateral Sclerosis, 2017
  4. Acta Neuropathologica, Understanding the Foundations of Clinicopathological Variability in TDP-43 Proteinopathies, 2019
  5. Acta Neuropathologica (Springer) — TDP-43 impairs glycolysis by sequestering hexokinase 1 in amyotrophic lateral sclerosis
  6. Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis
  7. A proposal for new diagnostic criteria for ALS
  8. European Academy of Neurology guideline on the management of amyotrophic lateral sclerosis
  9. Evidence-based consensus guidelines for ALS genetic testing and counseling
  10. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia - PMC
  11. Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results | Amylyx Pharmaceuticals, Inc.
  12. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS | New England Journal of Medicine
  13. Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
  14. Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis | Brain | Oxford Academic

Original Source(s)

Related Content